Keywords: Genzyme, Synvisc, Osteoarthritis, Japan approval, Reimbursement, Teijin

Japan approves Genzyme’s Synvisc for osteoarthritis of the knee and grants reimbursement

Article | 21 September 2010

Print This

There was some good news for troubled US biotech major Genzyme (Nasdaq: GENZ) which is hoping for an increased takeover ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in